SCTX (Scribe Therapeutics) Current Accrued Expense: $2.35 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $30.12
! 1 Warning Sign
View Full Analysis

What is Scribe Therapeutics Current Accrued Expense?

Scribe Therapeutics SCTX +1.06% 8 Current Accrued Expense is $2.35 Mil as of Dec. 2025. GuruFocus rates SCTX with a GF Score™ of 8/100. The stock has 1 warning sign investors should review.

Scribe Therapeutics's Current Accrued Expense for the quarter that ended in Dec. 2025 was $2.35 Mil.

Scribe Therapeutics's quarterly Current Accrued Expense increased from . 20 ($0.00 Mil) to Dec. 2024 ($2.48 Mil) but then declined from Dec. 2024 ($2.48 Mil) to Dec. 2025 ($2.35 Mil).

Scribe Therapeutics's annual Current Accrued Expense increased from . 20 ($0.00 Mil) to Dec. 2024 ($2.48 Mil) but then declined from Dec. 2024 ($2.48 Mil) to Dec. 2025 ($2.35 Mil).

Scribe Therapeutics Current Accrued Expense Related Terms

Scribe Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics Current Accrued Expense Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
Current Accrued Expense
2.48 2.35

Scribe Therapeutics Semi-Annual Data
Dec24 Dec25
Current Accrued Expense 2.48 2.35
SCTX
8GF Score
Scribe Therapeutics Inc SCTX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $2.35 Mil mean?
Scribe Therapeutics (SCTX) has a Current Accrued Expense of $2.35 Mil as of Dec. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on Scribe Therapeutics and its competitors.
Is Scribe Therapeutics' Current Accrued Expense too high?
Scribe Therapeutics' current Current Accrued Expense is $2.35 Mil. Overall, Scribe Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' Current Accrued Expense compare to ARTV and CABA?
Scribe Therapeutics' Current Accrued Expense of $2.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Scribe Therapeutics and its competitors. Scribe Therapeutics's current Current Accrued Expense is $2.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current Current Accrued Expense of $2.35 Mil. The current Current Accrued Expense is $2.35 Mil. Scribe Therapeutics' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current Current Accrued Expense is $2.35 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scribe Therapeutics Business Description

Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.12
Price